BackObsidian Therapeutics Overview

Obsidian Therapeutics Operating Income

Obsidian Therapeutics's operating income is $-86M.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

-$37.86M

As of Sep 30, 2026

Annual Operating Income (TTM)

-$85.79M

Trailing 12 months ending Sep 30, 2026

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Obsidian Therapeutics (OBX) FAQ

Obsidian Therapeutics posts a operating income of $-86M as of September 2026. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Operating Income is one piece of Obsidian Therapeutics's financial statement story. At $-86M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for OBX's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Obsidian Therapeutics's other metric pages and overview cover the third.

Judging Obsidian Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in operating income easier to interpret. Start with $-86M here, then scan peer and history charts to see if the gap is persistent.

Questions & Answers